Analysts at Jefferies Group cut their price target on shares of Pfizer (NYSE:PFE), to $36.00 in a research report issued to clients and investors on Monday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 20.56% from the stock’s previous close. Pfizer Inc. (NYSE:PFE), shares after opening at $30.15 moved to $30.22 on last trade day and at the end of the day closed at $30.09. Company price to sales ratio in past twelve months was calculated as 3.73 and price to cash ratio as 5.94. Pfizer Inc. (NYSE:PFE), showed a negative weekly performance of 3.65%.
Abbott Laboratories (NYSE:ABT), said its first-quarter earnings fell 31% as the health-care products company reported negative currency impacts masked modest overall sales growth. The bottom line topped the company’s own expectations, pushing shares up 1.4% to $38.50 premarket. Abbott Laboratories (NYSE:ABT), shares advanced 1.08% in last trading session and ended the day on $38.38. Abbott Laboratories (NYSE:ABT), return on equity ratio is recorded as 13.30% and its return on assets is 7.20%. Abbott Laboratories (NYSE:ABT), yearly performance is 5.01%.
Boston Scientific Corporation (NYSE:BSX), was once most cherished research and marketing pharmaceutical company of the U.S. pharmaceutical industry. Boston Scientific purchased rival Guidant Corp. for $ 27.3 billion in year 2006. Since then Boston Scientific was accused of paying a hefty premium for accusation and also the revenues for the company have not increased. But finally things have started turning up in the favor of Boston Scientific, company witnessed an increase in revenue. The company reported revenue of $1838 million for Q4 2013while for the same period in the year 2012 the company reported revenue of $1820 million. Boston Scientific Corporation (NYSE:BSX), shares moved up 1.12% in last trading session and was closed at $13.50, while trading in range of $ 13.37 – 13.64. Boston Scientific Corporation (NYSE:BSX), year to date (YTD) performance is 12.31%.
UnitedHealth Group Inc. (NYSE:UNH), was downgraded by Citigroup Inc. from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, Stock Ratings News reports. UnitedHealth Group Inc. (NYSE:UNH), weekly performance is -3.93%. On last trading day company shares ended up $78.19. UnitedHealth Group Inc. (NYSE:UNH), distance from 50-day simple moving average (SMA50) is 1.39%. Analysts mean target Price for the company is $84.86.